Equities research analysts at StockNews.com assumed coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) in a research report issued on Tuesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Trading Down 4.2 %
Shares of Titan Pharmaceuticals stock opened at $7.01 on Tuesday. The company has a fifty day simple moving average of $7.34 and a 200-day simple moving average of $7.17. Titan Pharmaceuticals has a 12-month low of $5.00 and a 12-month high of $16.60. The stock has a market cap of $6.38 million, a price-to-earnings ratio of -0.85 and a beta of 1.33.
About Titan Pharmaceuticals
Featured Stories
- Five stocks we like better than Titan Pharmaceuticals
- What Are Dividend Champions? How to Invest in the Champions
- It’s Time to Buy Into the Super Micro Computer Stock Implosion
- What are earnings reports?
- Merger or Not, Albertson’s Companies is a Good Buy
- Most Volatile Stocks, What Investors Need to Know
- 3 Cheap Stocks That Shouldn’t Be So
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.